Navigation Links
Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
Date:9/4/2012

MADISON, Wis., Sept. 4, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on Tuesday, September 11, 2012.  Mr. Palmin is scheduled to present at 10:50am ET in the Starlight North.  The event will be held September 9-11, at The Waldorf Astoria, 301 Park Avenue, New York, NY.

A live webcast of the Novelos presentation may be accessed via www.novelos.com

The webcast will be archived for 90 days following the presentation.

Information about the conference is available at www.rodm.com/conferences?id=176

About Novelos Therapeutics, Inc.
We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer.  Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells.  Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells.  This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.  I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent.  We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications.  I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.  We believe HOT also has first-in-class potential.  HOT Phase 1b dose-escalation trial is
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
2. Novelos Therapeutics Prices $5.4 Million Public Offering
3. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation ... Hip Stem, the latest addition to its growing ... is intended for use in total hip arthroplasty ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was developed ... philosophy. ODEV,s engineers worked closely with a select ...
(Date:9/2/2014)... , Sept. 2, 2014  PANTHERx Specialty ... Specialty Pharmacy Accreditation from URAC, a ... that establishes quality standards for the health care ... The URAC accreditation process demonstrates ... a framework to improve business processes through benchmarking ...
Breaking Medicine Technology:Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Ortho Development Receives FDA Clearance for Alpine Hip Stem 2PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2
... DEERFIELD, Ill. , April 28 ... and its wholly owned subsidiary, Takeda Pharmaceuticals North America, ... of eight defendants in patent infringement litigation brought against ... Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl) and ACTO ...
... Texas , April 27 Lexicon Pharmaceuticals, ... on discovering and developing breakthrough treatments for human disease, announced ... presentations on results from its Phase 2 clinical study with ... (IBS) at Digestive Disease Week (DDW) 2010 in New ...
Cached Medicine Technology:Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 2Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 3Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 4Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 5Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 6Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 7Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 8Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week 2Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week 3
(Date:9/2/2014)... be a new salve to dominate medicine cabinets of the ... Salamanders may not be the cuddliest of animals, but they ... damaged body parts. Now, a new report published in the ... , identifies a small protein (called a "peptide") from the ... the secret of this amazing wound healing trick in humans. ...
(Date:9/2/2014)... made it clear that a mother,s eating habits prior ... profound impact on her offspring and their propensity for ... the mechanisms behind this phenomenon were unclear. According to ... The FASEB Journal F , scientists using ... mother,s diet and an offspring,s risk of future obesity. ...
(Date:9/2/2014)... 2014 Concorde Career College North ... receive the 2014 Excellence in Community Service Award ... Colleges (ACCSC). , Every year, the Accrediting Commission ... who make outstanding contributions in their local community ... the scope and impact of the community service ...
(Date:9/2/2014)... that the key to more youthful immune function might ... published in the Journal of Leukocyte Biology ... of old mice had different responses to Mycobacterium ... changes were reversed by ibuprofen. , "Inflammation in old ... Joanne Turner, Ph.D., a researcher involved in the work ...
(Date:9/2/2014)... Splashtop Inc. , the worldwide ... NTT DoCoMo to deliver Splashtop Business Lite ... Lite is included in NTT DoCoMo’s “Business Plus” program. ... that empower users to remote access their corporate computers ... 18 million users worldwide. Splashtop delivers the best ...
Breaking Medicine News(10 mins):Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2
... Barbara Davis Center for Childhood Diabetes at the University ... against type 1 diabetes: The Juvenile Diabetes Research Foundation ... JDRF Autoimmunity Center at the Barbara Davis Center for ... Autoimmunity Center will receive approximately $1 million a year ...
... are lucky in love. , At least thats how ... research on the mating habits and nervous systems of ... both the voles behavior and their brains, appears in ... Academy of Sciences. , Prairie voles, aka Microtus ochrogaster, ...
... 28 The Department of,Veterans Affairs (VA) today ... Marion, Ill., hospital. The VA today released the ... at the Marion,facility., VA,s Inspector General was ... for Health, on September 10, 2007 and also ...
... Reasons for the association are unknown, researchers say , , ... Korean study found frequent snoring was associated with the ... they aren,t sure why. , "The mechanisms underlying the ... said the report, published in the Jan. 28 issue ...
... to Launch Vitals.com Which Offers Free Comprehensive Doctor ... Information and ... ), one of the,nation,s top 10 public relations firms, today announced ... and execute a,comprehensive communications program for the free, online doctor evaluation,service., ...
... the use of financial,incentives for health care ... non-profit National Business,Coalition on Health (NBCH) recently ... discuss an emerging trend in employer-sponsored health,care: ... choice of,healthier lifestyles and high value medical ...
Cached Medicine News:Health News:JDRF to establish an autoimmunity center at University of Colorado Denver 2Health News:Zoologists: Lusty voles, mindless of danger, mate like rabbits 2Health News:Zoologists: Lusty voles, mindless of danger, mate like rabbits 3Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 2Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 3Health News:VA Leadership Vows to Fix Problems Identified at Marion VA Medical Center 4Health News:Study Links Snoring to Chronic Bronchitis 2Health News:MWW Group Selected by First-Ever Online Doctor Evaluation Service Vitals.com 2Health News:National Business Coalition on Health Convenes Multi-Stakeholder Leadership Group to Address Value Based Purchasing Trends 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... 3-Point® Polycentric Hinged Ulnar Deviation Splint ... align the hand with ulnar deviation at ... impede grasp or pinch. Radial and ulnar ... ensure unimpeded flexion and extension. Padded, malleable ...
... immobilizes and positions the elbow at 122 ... prominent. Restricts full extension and flexion to ... helps prevent pain and irritation due to ... post-cast removal. Rigid, high-density beige polyethylene shell ...
... Orthosis For quick, efficient immobilization of ... immobilizes and protects the fracture and ... comfort, support, and conformity to the ... shell may be gently heated (with ...
Medicine Products: